In the comparison CO₂ vs iodine in peripheral angiography, the most frequent problem is not “CO₂ does not work,” but rather a clinical-technical decision made under pressure: a poorly selected target, unsynchronized acquisition, or unmanaged fallback. This article is for interventional radiologists, vascular surgeons, and healthcare administrators who want to make a CO₂-first/contrast-sparing strategy defensible in patients with CKD (chronic kidney disease) or allergies, reducing operator-dependent variability through protocols and traceability.
CO₂ is a negative contrast agent: image quality depends more than usual on geometry, positioning, and timing. If these key points are not standardized, the “poor image” becomes the emotional trigger for returning to iodine, often more than necessary.
In the hybrid operating room or angiography suite, the decision is influenced by three factors: procedure time, perceived risk — for example, a fragile patient or complex lesion — and accountability, meaning the need to justify the reason behind a choice. When there is no shared protocol, iodine becomes the shortcut because it is familiar, even though it increases exposure in patients at risk of AKI/CIN (acute kidney injury/contrast-induced nephropathy).
The solution is not “using more CO₂,” but making better decisions and making what works repeatable: the same steps, the same criteria, and the same recorded parameters. This is where standardization and traceability transform CO₂ from a “craft-based” technique into a clinical strategy.
CO₂ in angiography is widely used below the diaphragm — peripheral vascularization, iliac-femoral districts, and more distal territories, in many assessment/run-off strategies — especially when the objective is to reduce or avoid iodine in patients with CKD or allergy to iodinated contrast media. The first decision-making error is treating “peripheral” as a single category and expecting the same performance in every anatomy and every projection.
A target selected without considering flow direction, the presence of severe stenoses, collaterals, and vessel volume leads to incomplete filling and to an image that appears “not to hold up.” In reality, it is the target that needs a different approach: changing access, changing the segment to opacify, or segmenting the examination into shorter, more controlled steps.
The correct decision is to define in advance: (1) which segment must answer which question — diagnostic vs treatment guidance — and (2) when CO₂ is the primary contrast agent and when it is complementary. In a contrast-sparing pathway, iodine is not “forbidden”: it is reserved for moments with high informational value, not used as a generic solution at the first suboptimal image.
The second critical point is the idea that, if the image is poor, more injections or more volume are needed. In reality, CO₂ is sensitive to catheter positioning, angulations, latency between injection and acquisition, and hemodynamic conditions. Misaligned timing produces an “empty” frame, and the team concludes that CO₂ is not adequate.
What makes the difference here is a workflow that requires the same check before labeling the image as a failure: confirmation of positioning, definition of the acquisition window, and consistency between the segment being studied and the projection. CO₂ does not forgive variability: what remains “acceptable” with iodine becomes “uninterpretable” with CO₂.
Standardization also reduces the “trial-and-error” bias: fewer unnecessary runs, fewer undocumented setting changes, and more comparison between cases. A system that enables traceability of injection parameters — pressure, volume, timing, according to the available configuration — makes it possible to correlate image performance and settings, transforming a subjective impression into replicable data.
In this sense, automatic and digital platforms such as Angiodroid have an organizational role as well as a technical one: they make delivery more consistent than manual injection and create a common language among operators, which is also useful for training and internal audits.
The third decision point is the most delicate: fallback to iodine is clinically legitimate, but it must be governed. Without criteria, fallback becomes a habit: “if it is not perfect on the first attempt, use iodine.” In a CKD patient, this behavior shifts the risk toward AKI/CIN, lengthens care pathways, and makes it difficult to demonstrate value to healthcare administrators.
The defensible strategy is not CO₂-only in every case, but CO₂-first with a defined fallback that is documented and shared. Fallback should answer a precise question: “Is this information necessary right now for safety or technical success?” If the answer is yes, iodine is used in a targeted way, with the minimum effective volume.
To make the decision objective, an internal protocol should include a criteria grid that separates: (a) correctable technical error — positioning/timing; (b) anatomical/physiological limitation of the case; and (c) non-substitutable informational need. Once the criteria have been standardized, the operator does not “choose against CO₂”: they apply a process that protects both patient and team.
When CO₂ is integrated into a protocol, the output is not just an image: it is a measurable workflow. Standardization means reducing differences between operators, making performance more predictable, and making the CO₂-first choice “defensible” in front of colleagues, risk management, and healthcare administrators.
Traceability of injection parameters and procedural steps enables three practical advantages: faster learning — training based on cases and data; auditing — understanding why a case went well or poorly; and clinical governance — defining KPIs such as volumes of iodine avoided, percentage of contrast-sparing procedures, and post-procedure renal events. In Europe and Italy, this type of approach aligns with value-based care and sustainability principles.
If you want to transform CO₂ from an option used “when it works” into a contrast-sparing strategy, we can support you with an operational package: a set-up and timing checklist, fallback criteria that can be shared with the team, and a mini-audit structure to measure iodine volumes and variability among operators.
Request a demo and an assessment of your CO₂ workflow or contact us to plan a “CO₂-first” launch workshop at your center.
CO₂ is a negative contrast agent, and image quality depends critically on catheter positioning, vessel geometry, and acquisition timing. With iodine, small errors often remain “acceptable,” whereas with CO₂ they become immediately visible. When set-up and synchronization are standardized, performance becomes more stable and fallback to iodine decreases.
A CO₂-first strategy is particularly relevant in patients with chronic kidney disease (CKD), diabetes, or high risk of AKI/CIN, and in patients with allergy to iodinated contrast media. The goal is to reduce or eliminate exposure to iodine while maintaining sufficient information for decision-making and treatment. The protocol must still include clear criteria for the targeted use of iodine when clinically necessary.
Fallback is the switch to iodine when CO₂ does not provide the information needed for safety or technical success. The decision must be guided by objective criteria: first, technical errors such as positioning and timing are corrected; then, the team assesses whether there is an anatomical limitation or a non-substitutable informational need. In this way, iodine does not replace CO₂ “out of habit,” but is used in a targeted and defensible manner.
Traceability makes it possible to connect image quality with procedural settings, transforming subjective assessments into replicable data. It helps reduce variability between operators, accelerates the learning curve, and supports internal audits on avoided iodine volumes and adherence to the protocol. This makes it easier to justify a CO₂-first strategy from the perspective of patient safety and clinical governance.
Yes, because automation reduces operator-dependent variability and facilitates more consistent delivery, while also supporting workflow standardization. In addition, digital systems can enable traceability and comparison between cases, which are useful for training and quality improvement. This approach is consistent with the adoption of contrast-sparing pathways in fragile renal patients or allergic patients.
Map the vascular segments to be studied and associate each one with a question — diagnosis, planning, or treatment guidance. Identify in which steps CO₂ is the primary contrast agent and in which iodine is allowed only as targeted completion, especially in CKD or allergic patients.
Introduce a checklist before declaring an “uninterpretable image”: confirmation of catheter positioning, choice of projection, and synchronization between injection and acquisition. Reduce undocumented attempts and establish a maximum number of technical corrections before evaluating fallback.
Formalize criteria that distinguish between correctable technical error, case limitation, and informational need for safety. When iodine is used, define the “minimum effective volume” and record the clinical reason for fallback, so the strategy remains defensible and auditable.
Collect procedural parameters and operational outcomes — iodine volumes, percentage of contrast-sparing procedures, and reasons for fallback. Use the data for internal training and to align the team around a common language; automatic and digital tools facilitate this step.